Quote:

---

Long Covid results -- 4/2024.

---

What I find perplexing is that in the FDA submitted protocol there was no exclusion for CCR5 delta 32 double allele deletion. Even though there was a more balanced population than in the NASH trial a few carrying that genetic mutation on either side could skew the results. At minimum every trial going forward should have that exclusion in place.

Long Covid and ME/CFS indications should be pursued but with larger trial populations. But not until FDA approvals are in place and Cytodyn has revenue rolling in.